Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Asher Biotherapeutics, Inc. currently holds 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio involves a distinct examiner and a single art unit. The focus on biotechnology suggests that the company's current intellectual property efforts are directed toward complex biological or pharmaceutical developments.
JOHANSEN, PETER N. is the busiest examiner for the company. This examiner is managing 1 busiest examiner pending office action, which accounts for all active office actions currently facing the company. A centralized prosecution structure like this one provides the benefit of consistent feedback from the USPTO, as all concerns originate from a single source.
For the practitioner, the primary challenge is to address the specific technical requirements of the assigned examiner and art unit. The alignment of the technology area with the art unit indicates that the application is being reviewed by specialists in the biotech sector. Effective prosecution will require a detailed understanding of the examiner's previous actions and the specific legal standards applied within this art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039608 | FUSIONS OF MUTANT INTERLEUKIN-10 POLYPEPTIDES WITH ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION | JOHANSEN, PETER N. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039608 | FUSIONS OF MUTANT INTERLEUKIN-10 POLYPEPTIDES WITH ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION | JOHANSEN, PETER N. | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18039608 | FUSIONS OF MUTANT INTERLEUKIN-10 POLYPEPTIDES WITH ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION | JOHANSEN, PETER N. | 1644 | §102§103§112 | Non-Final OA | — | Pending | May 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAsher Biotherapeutics, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Peter N. Johansen has the most, with 1 of Asher Biotherapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
